Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 952-958

  Kobayashi, Masashi ^a   Huang, Cheng Long ^a   Sonobe, Makoto ^a   Kikuchi, Ryutaro ^a   Ishikawa, Masashi ^a   Kitamura, Jiro ^a   Miyahara, Ryo ^a   Menju, Toshi ^a   Iwakiri, Shotaro ^b   Itoi, Kazumi ^b   Yasumizu, Ryoji ^c   Date, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^c Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

C Myc; Mesothelioma; Prognosis; Proliferation; Survivin; Wnt2B

Indexed keywords

KI 67 ANTIGEN; MYC PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; WNT1 PROTEIN; WNT2 PROTEIN; WNT2B PROTEIN; WNT5A PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURAL MESOTHELIOMA; NICK END LABELING; PLEURA MESOTHELIOMA; PROGNOSIS; PROTEIN EXPRESSION;

EID: 84859459240     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.511     Document Type: Article

References (34)

1. Greillier L and Astoul P: Mesothelioma and asbestos-related pleural diseases. Respiration 76: 1-15, 2008.
2. Bueno R: Mesothelioma clinical presentation. Chest 116 (Suppl6): S444-S445, 1999.
3. Fujimoto N, Aoe K, Gamba K, Kato K, Yamazaki K and Kishimoto T: Clinical investigation of malignant mesothelioma in Japan. J Cancer Res Clin Oncol 136: 1755-1759, 2010.
4. Schil PE, Bass P, Gaafar R, et al: Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 36: 1362-1369, 2010.
5. Dale TC: Signal transduction by the Wnt family of ligands. Biochem J 329: 209-223, 1998.
6. You Z, Saims D, Chen S, et al: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440, 2002.
7. Huang C, Liu D, Masuya D, et al: MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene 23: 7475-7483, 2004.
8. Huang C, Liu D, Ishikawa S, et al: Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 44: 2680-2688, 2008.
9. Huang C, Liu D, Nakano J, et al: Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-A expression in non-small cell lung cancer. J Clin Oncol 23: 8765-8773, 2005.
10. Chen G, Shukeir N, Potti A, et al: Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101: 1345-1356, 2004.
11. Zhang WM, Lo Muzio L, Rubini C and Yan G: Effect of WNT-1 on β-catenin expression and its relation to Ki-67 and tumor differentiation in oral squamous cell carcinoma. Oncol Rep 13: 1095-1099, 2005.
12. Lee A, Raz DJ, He B and Jablons DM: Update on the molecular biology of malignant mesothelioma. Cancer 109: 1454-1461, 2007.
13. Kim PJ, Plescia J, Clevers H, Fearon ER and Altieri DC: Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209, 2003.
14. Ma H, Nguyen C, Lee KS and Kahn M: Differential roles for the coactivators CBP and p300 on TCF/β-catenin-mediated survivin gene expression. Oncogene 24: 3619-3631, 2005.
15. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
16. Husain AN, Colby TV, Ordonez NG, et al: Guidelines for pathologic diagnosis of malignant mesothelioma. Arch Pathol Lab Med 133: 1317-1331, 2009.
17. Attanoos RL and Gibbs AR: Pathology of malignant mesothelioma. Histopathology 30: 403-418, 1997.
18. Nakano J, Huang C, Liu D, et al: The clinical significance of splice variants and subcellular localization of survivin in non-small cell lung cancer. Br J Cancer 98: 1109-1117, 2008.
19. Katoh M, Kirikoshi H, Terasaki H and Shiokawa K: WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT-beta-catenin-TCF signaling pathway. Biochem Biophys Res Commun 289: 1093-1098, 2001.
20. Zhang X, Gaspard JP and Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61: 6050-6054, 2001.
21. Lu CD, Altieri DC and Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58: 1808-1812, 1998.
22. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and TanigawaN: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998.
23. Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005, 2008.
24. Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
25. Adams RR, Carmena M and Earnshaw WC: Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11: 49-54, 2001.
26. Martinez A, Bellosillo B, Bosch F, et al: Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164: 501-510, 2004.
27. Shinohara ET, Gonzalez A, Massion PP, et al: Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 103: 1685-1692, 2005.
28. Brennan DJ, Rexhepaj E, O'Brien SL, et al: Altered cytoplasmic-to nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14: 2681-2689, 2008.
29. Dang CV, Resar LM, Emison E, et al: Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253: 63-77, 1999.
30. Yang G, Timme TL, Frolov A, Wheeler TM and Thompson TC: Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103: 1186-1194, 2005.
31. Lu D, Kadota K, Ueno M, Nakashima N, Yokomise H and Huang CL: Adenoviral vector expressing short hairpin RNA targeting Wnt2B has an effective antitumour activity against Wnt2B2-overexpressing tumours. Eur J Cancer: Jun 4, 2011 (Epub ahead of print).
32. Rao DD, Vorhies JS, Senzer N, et al: siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61: 746-759, 2009.
33. Ma B, Zhang S, Jiang H, Zhao B and Lv H: Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release 123: 184-194, 2007.
34. Watanabe Y, Kojima T, Kagawa S, et al: A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene 29: 1145-1154, 2010.